Skip to main content
ALT
NASDAQ Life Sciences

Altimmune Q3 Loss Widens to $31.6M, Missing Estimates as Trial Costs Climb

Tom Rudovsky · Reported by Reuters
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$1.915
Mkt Cap
$375.419M
52W Low
$1.9
52W High
$6.44
52W Position info
0.8% above low
Off High info
70% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

ALT is trading near its 52-week low of $1.9 (0.8% above the low).

Summary

Altimmune posted a Q3 net loss of $31.6 million, or $0.15 a share, wider than the $25.48 million consensus and well above the $19.0 million loss a year ago. Operating expenses ran $35.71 million with R&D at $27 million, driven by the Phase 3 PERFORMA MASH trial and the Phase 2 RESTORE ALD trial, plus higher compensation and professional services costs. Cash, equivalents and investments stood at $480 million at quarter end, down from $519 million at the end of Q2 — a modest burn relative to the balance sheet, so dilution is not an immediate concern. The miss is a cost-line story, not a pipeline setback: PERFORMA is on track with 52-week topline in 2029, RESTORE topline is expected in the second half of 2027, and an end-of-Phase 2 meeting with the FDA for the AUD program is set for December 2026. With the stock at $1.92 near its 52-week low of $1.90, the December FDA meeting is the next scheduled item that can change the story.

At the time of this announcement, ALT was trading at $1.92 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $375.4M. The 52-week trading range was $1.90 to $6.44. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.


Price Chart

Share this article

Copied!

ALT - Latest Insights

ALT
Nov 09, 2026, 12:30 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $2.14
Real-time Price: $1.90 info
Change: -$0.235 (-11%) info
Market Cap: $375.419M info
ALT
Aug 12, 2026, 4:04 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $2.96
Real-time Price: $1.90 info
Change: -$1.06 (-36%) info
Market Cap: $375.419M info
ALT
Aug 12, 2026, 7:43 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $3.06
Real-time Price: $1.90 info
Change: -$1.16 (-38%) info
Market Cap: $375.419M info
ALT
Aug 12, 2026, 7:33 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.01
Real-time Price: $1.90 info
Change: -$1.11 (-37%) info
Market Cap: $375.419M info
ALT
Jul 28, 2026, 7:04 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.44
Real-time Price: $1.90 info
Change: -$1.54 (-45%) info
Market Cap: $375.419M info